WO2022251427A1 - Detecting and correcting for interference in an analyte monitoring system - Google Patents
Detecting and correcting for interference in an analyte monitoring system Download PDFInfo
- Publication number
- WO2022251427A1 WO2022251427A1 PCT/US2022/031035 US2022031035W WO2022251427A1 WO 2022251427 A1 WO2022251427 A1 WO 2022251427A1 US 2022031035 W US2022031035 W US 2022031035W WO 2022251427 A1 WO2022251427 A1 WO 2022251427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analyte
- indicator
- interferent
- measurement
- amount
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 658
- 238000012544 monitoring process Methods 0.000 title claims description 79
- 238000005259 measurement Methods 0.000 claims abstract description 325
- 230000015556 catabolic process Effects 0.000 claims abstract description 93
- 238000006731 degradation reaction Methods 0.000 claims abstract description 93
- 230000000694 effects Effects 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 61
- 238000010521 absorption reaction Methods 0.000 claims abstract description 37
- 230000005284 excitation Effects 0.000 claims description 173
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 230000003647 oxidation Effects 0.000 description 50
- 238000007254 oxidation reaction Methods 0.000 description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 32
- 239000008103 glucose Substances 0.000 description 32
- 230000006870 function Effects 0.000 description 27
- 238000004891 communication Methods 0.000 description 23
- 239000003642 reactive oxygen metabolite Substances 0.000 description 22
- 230000007423 decrease Effects 0.000 description 21
- 230000008569 process Effects 0.000 description 21
- 239000000758 substrate Substances 0.000 description 20
- 230000008859 change Effects 0.000 description 17
- 230000001939 inductive effect Effects 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 210000003722 extracellular fluid Anatomy 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 229940126062 Compound A Drugs 0.000 description 12
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- CNQCVBJFEGMYDW-UHFFFAOYSA-N lawrencium atom Chemical compound [Lr] CNQCVBJFEGMYDW-UHFFFAOYSA-N 0.000 description 8
- 239000004065 semiconductor Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 5
- 238000009529 body temperature measurement Methods 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010061951 Methemoglobin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 108010064719 Oxyhemoglobins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- VDBJCDWTNCKRTF-UHFFFAOYSA-N 6'-hydroxyspiro[2-benzofuran-3,9'-9ah-xanthene]-1,3'-dione Chemical compound O1C(=O)C2=CC=CC=C2C21C1C=CC(=O)C=C1OC1=CC(O)=CC=C21 VDBJCDWTNCKRTF-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000012623 in vivo measurement Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000036202 glucose binding proteins Human genes 0.000 description 1
- 108091011004 glucose binding proteins Proteins 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical group CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6861—Capsules, e.g. for swallowing or implanting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/04—Arrangements of multiple sensors of the same type
- A61B2562/046—Arrangements of multiple sensors of the same type in a matrix array
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N2021/7769—Measurement method of reaction-produced change in sensor
- G01N2021/7786—Fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- the present invention relates generally to detecting and correcting for interference in an analyte monitoring system.
- the interference may include blood in a medium (e.g., interstitial fluid) and/or an effect (e.g., oxidation-induced degradation) on an analyte indicator in the analyte monitoring system,
- Analyte monitoring systems may be used to monitor analyte levels, such as analyte concentrations (e.g., glucose concentrations).
- analyte concentrations e.g., glucose concentrations.
- One type of analyte monitoring system is a continuous analyte monitoring system, A continuous analyte monitoring system measures analyte levels throughout the day and can be very useful in the management of diseases, such as diabetes.
- Some analyte monitoring systems include an analyte sensor, which may be implanted (fully or partially) in an animal and may include an analyte indicator. Blood in interstitial fluid in proximity to the analyte indicator and/or an effect on the analyte indicator may interfere with the accurate measurement of the analyte (e.g., glucose) by the analyte sensor.
- the analyte sensor may lose sensitivity while Implanted in the animal as a result of changes in sensitivity parameters (e.g., calibration constants). The changes in sensitivity parameters may be due to, for example, degradation of the analyte indicator.
- the degradation may be caused by, for example, oxidation of the analyte indicator induced by cellular generated reactive oxygen species (ROS).
- ROS reactive oxygen species
- the rate in vivo sensitivity loss can be reduced by, for example, using oxidation resistant indicator molecules, integrating catalytic protection, and/or using a membrane that catalyzes degradation of reactive oxygen species (ROS).
- ROS reactive oxygen species
- the gradual change in sensitivity parameters over time may negatively affect analyte sensing accuracy and may necessitate re-calibrations using reference analyte measurements (e.g., self-monitoring blood glucose measurements), which may be uncomfortable and/or otherwise undesirable for a user.
- reference analyte measurements e.g., self-monitoring blood glucose measurements
- the present invention overcomes the disadvantages of prior systems by providing an analyte monitoring system capable of detecting and correcting for one or more interferents.
- the one or more interferents may interfere with the accurate measurement of an analyte (e.g., glucose) in a medium (e.g., interstitial fluid).
- the one or more interferents may include blood in the medium.
- the one or more interferents may include an effect on an analyte indicator of the analyte sensor.
- the analyte monitoring system may provide, among other advantages, the ability to correct for one or more interferents without the need for a reference analyte measurement.
- the analyte monitoring system may include an analyte sensor that measures the one or more interferents using an interferent indicator.
- the interferent indicator not not be sensitive to the analyte.
- the interferent indicator may have one or more properties that vary with the effect (e.g., degradation by reactive oxygen species (1108)) on the analyte indicator.
- the one or more properties of the interferent indicator may include an absorption that varies in accordance with the effect on the analyte indicator. In some aspects, the one or more properties of the interferent indicator may include optical properties that vary' in accordance with the effect on the analyte indicator. In some aspects, the interferent indicator may be used as a reference dye for measuring and correcting for the effect on the analyte indicator. In some aspects, the analyte monitoring system may correct for the one or more interferents using an empiric correlation established through laboratory' testing.
- the analyte sensor may include an analyte indicator, a degradation indicator, and sensor elements.
- the analyte indicator may be configured to exhibit a first detectable property that varies in accordance with (i) an amount or concentration of the analyte in the medium and (ii) an extent to which the analyte indicator has degraded.
- the degradation indicator may be configured to exhibit a second detectable property that varies in accordance with an extent to which the degradation indicator has degraded. The extent to which the degradation indicator has degraded may correspond to the extent to which the analyte indicator has degraded.
- the sensor elements may be configured to generate (i) an analyte measurement based on the first detectable property exhibited by the analyte indicator and (ii) a degradation measurement based on the second detectable property exhibited by the degradation indicator.
- the extent to which the degradation indicator has degraded may be proportional to the extent to which the analyte indicator has degraded
- degradation to the analyte indicator may include reactive oxidation species (ROS)-induced oxidation
- degradation to the degradation indicator includes ROS-induced oxidation
- the analyte indicator may be a phenylboronic-based analyte indicator.
- the degradation indicator may be a phenylboronic-based degradation indicator.
- the analyte sensor may further include an indicator element comprising the analyte indicator and the degradation indicator.
- the analyte indicator may include analyte indicator molecules distributed throughout the indicator element
- the degradation indicator may include degradation indicator molecules distributed throughout the indicator element.
- the second detectable property does not vary in accordance with the amount or concentration of the analyte in the medium.
- the sensor elements may include a first light source and a first photodetector.
- the first light source may be configured to emit first excitation light to the analyte indicator.
- the first photodetector configured to receive first emission light emitted by the analyte indicator and output the analyte measurement.
- the analyte measurement may be indicative of an amount of first emission light received by the first photodetector.
- the sensor elements may include a second light source and a second photodetector.
- the second light source may be configured to emit second excitation light to the degradation indicator.
- the second photodetector may be configured to receive second emission light emitted by the degradation indicator and output the degradation measurement.
- the degradation measurement may be indicative of an amount of second emission light received by the second photodetector.
- the first photodetector may be configured to receive second excitation light reflected from the indicator element and output a first reference signal indicative of an amount of reflected second excitation light received by the first photodetector.
- the sensor elements may include a third photodetector configured to receive first excitation light reflected from the indicator element and output a second reference signal indicative of an amount of reflected first excitation light received by the third photodetector.
- Another aspect of the invention may provide a method including using an analyte indicator of an analy te sensor to measure an amount or concentration of an analyte in a medium. The method may include using a degradation indicator of the analyte sensor to measure an extent to which the degradation indicator has degraded. The method may include using a sensor interface device of a transceiver to receive from the analyte sensor an analyte measurement indicative of the amount or concentration of the analyte in the medium.
- the method may include using the sensor interface device of the transceiver to receive from the analyte sensor a degradation measurement indicative of the extent to which the degradation indicator has degraded.
- the method may include using a controller of the transceiver to calculate an extent to which the analyte indicator of the analyte sensor has degraded based at least on the received degradation measurement.
- the method may include using the controller of the transceiver to adjust a conversion function based on the calculated extent to which the analyte indicator has degraded.
- the method may include using the controller of the transceiver to calculate an analyte level using the adjusted conversion function and the received analyte measurement.
- the method may include displaying the calculated analyte level.
- Still another aspect of the invention may provide an analyte monitoring system including an analyte sensor and a transceiver.
- the analyte sensor may include an analyte indicator, a degradation indicator, sensor elements, and a transceiver interface device.
- the analyte indicator may be configured to exhibit a first detectable property that varies in accordance with (i) an amount or concentration of an analyte in a medium and (ii) an extent to which the analyte indicator has degraded.
- the degradation indicator may be configured to exhibit a second detectable property that varies in accordance with an extent to which the degradation indicator has degraded.
- the sensor elements may be configured to generate (i) an analyte measurement based on the first detectable property exhibited by the analyte indicator and (ii) a degradation measurement based on the second detectable property exhibited by the degradation indicator.
- the transceiver may include a sensor interface device and a controller.
- the controller may be configured to: (i) receive the analyte measurement from the analyte sensor via the transceiver interface device of the analyte sensor and the sensor interface device; (ii) receive the degradation measurement from the analyte sensor via the transceiver interface device of the analyte sensor and the sensor interface device; (iii) calculate an extent to which the analyte indicator of the analyte sensor has degraded based at least on the received degradation measurement; (ivj adjust a conversion function based on the calculated extent to which the analyte indicator has degraded; and (v) calculate an analyte level using the adjusted conversion function and the received analyte measurement.
- the analyte sensor may further include an indicator element, and the indicator element may include the analyte indicator and the degradation indicator.
- the second detectable property does not vary- in accordance with the amount or concentration of the analyte in the medium.
- an analyte monitoring system including an analyte indicator, an interferent indicator, sensor elements, and a controller.
- the analyte indicator may have a first detectable property that varies in accordance with at least (i) an amount or concentration of an analyte in a medium and (ii) an effect on the analyte indicator.
- the interferent indicator may have an absorption that varies in accordance with the effect on the analyte indicator.
- the sensor elements may be configured to generate (i) an analyte measurement based on the first detectable property of the analyte indicator and (ii) a reference measurement based on at least the absorption of the interferent indicator.
- the controller may be configured to; (i) calculate the effect on the analyte indicator based at least on the reference measurement, (ii) adjust a conversion function based on at least the calculated effect on the analyte indicator, and (iii) calculate an analyte level using the adjusted conversion function and the analyte measurement.
- the effect on the analyte indicator may be degradation of the analyte indicator.
- the system may further include an indicator element that comprises the analyte indicator and the interferent indicator, the analyte indicator may include analyte indicator molecules distributed throughout the indicator element, and the interferent indicator may include interferent indicator molecules distributed throughout the indicator element.
- the sensor elements a first light source configured to emit first excitation light, to the analyte indicator and a signal photodetector configured to receive first emission light emitted by the analyte indicator and output the analyte measurement, and the analyte measurement may be indicative of an amount of the first emission light received by the signal photodetector.
- the sensor elements may further include a second light source configured to emit second excitation light, to the interferent indicator.
- the signal photodetector may be further configured to receive an amount of the second excitation light and output the reference measurement, the reference measurement may be indicative of the amount of the received second excitation light, and the amount of the received second excitation light may be indicative of the absorption of the interferent indicator.
- the sensor elements may further include a reference photodetector configured to receive an amount of the second excitation light and output the reference measurement, the reference measurement may be indicative of the amount of the received second excitation light, and the amount of the received second excitation light may be indicative of the absorption of the interferent indicator.
- the sensor elements may further include an interferent photodetector configured to receive second emission light emitted by the interferent indicator and output an interferent measurement indicative of an amount of the second emission light received by the interferent photodetector.
- the second emission light may van, ' in accordance with the effect on the analyte indicator.
- the sensor elements may include a first reference photodetector configured to receive an amount of the first, excitation light and output a first reference measurement indicative of the amount of the received first excitation light.
- the second emission light emitted by the interferent indicator does not vary' in accordance with the amount or concentration of the analyte in the medium.
- the processor may be configured to calculate the effect on the analyte indicator based at least on the reference measurement and the interferent measurement. In some aspects, the processor may be configured to calculate the effect on the analyte indicator based at least on a ratio of the interferent measurement and the reference measurement.
- the processor may be further configured to calculate an amount of blood in the medium.
- the processor may be configured to adjust the conversion function based on at least the calculated effect on the analyte indicator and the calculated amount of blood in the medium.
- the reference measurement may be a second reference measurement, and the sensor elements may include a first light source, a second light source, a first reference photodetector, and a signal photodetector.
- the first light source may be configured to emit first excitation light to the analyte indicator
- the second light source may be configured to emit second excitation light to the interferent indicator
- the first reference photodetector may be configured to receive an amount of the first, excitation light and output a first reference measurement indicative of the amount of the received first excitation light
- the signal photodetector may be configured to (i) receive first emission light emitted by the analyte indicator and output the analyte measurement and (ii) receive an amount of the second excitation light and output the second reference measurement.
- the analyte measurement may be indicative of the amount of the received first emission light
- the second reference measurement may be indicative of the amount of the received second excitation light.
- the reference measurement may be a second reference measurement
- the sensor elements include a first light source, a second light source, a first reference photodetector, and a signal photodetector.
- the first light source may be configured to emit first excitation light to the analyte indicator
- the second light, source may be configured to emit second excitation light to the interferent indicator
- the first reference photodetector may be configured to receive an amount of the first excitation light and output a first reference measurement indicative of the amount of the received first excitation light
- the signal photodetector may be configured to receive first emission light emitted by the analyte indicator and output the analyte measurement
- the analyte measurement may be indicative of an amount of the received first emission light
- the second reference photodetector may be configured to receive an amount of the second excitation light and output the second reference measurement
- the second reference measurement may be indicative of the amount of the received second excitation light.
- the processor may be configured to calculate the amount of blood in the medium based on at least the first and second reference measurements. In some aspects, the processor may be configured to calculate the amount of blood in the medium based on at least a ratio of the first and second reference measurements.
- the sensor elements may include an interferent photodetector configured to receive emission light emitted by the interferent indicator and output an interferent measurement indicative of an amount of the emission light received by the interferent photodetector, and the processor may be configured to calculate the amount of blood in the medium based on at least the interferent measurement.
- the interferent indicator may have a second detectable property that varies in accordance with the effect on the analyte indicator
- the sensor elements may be further configured to generate an interferent measurement based on the second detectable property of the analyte indicator
- the processor may be configured to calculate the effect on the analyte indicator based at least on the reference measurement, and the interferent measurement.
- the processor may he configured to calculate the effect on the analyte indicator at least based on a ratio of the interferent measurement and the reference measurement.
- Still another aspect of the invention may provide a method including using an analyte indicator to generate an analy te measurement, indicative of an amount or concentration of an analyte in a medium, and the analyte measurement may vary 7 in accordance with at least an effect on the analyte indicator.
- the method may include using an interferent indicator to generate a reference measurement indicative of an absorption of the interferent indicator, and the absorption may vary' in accordance with the effect on the analyte indicator.
- the method may include calculating the effect on the analyte indicator based at least on the reference measurement.
- the method may include adjusting a conversion function based on at least the calculated effect on the analyte indicator.
- the method may include calculating an analyte level using the adjusted conversion function and the analyte measurement.
- the effect on the analyte indicator may be degradation of the analyte indicator.
- using the analyte indicator to generate the analyte measurement may include emitting first excitation light to the analyte indicator and using a signal photodetector configured to receive first emission light emitted by the analyte indicator and output the analyte measurement, and the analyte measurement may be indicative of an amount of the first emission light received by the signal photodetector.
- using the interferent indicator to generate the reference measurement may include emitting second excitation light to the interferent indicator.
- using the interferent indicator to generate the reference measurement may further include using the signal photodeteetor to receive an amount of the second excitation light and output the reference measurement, the reference measurement may be indicative of the amount of the received second excitation light, and the amount of the received second excitation light may he indicative of the absorption of the interferent indicator.
- using the interferent indicator to generate the reference measurement may further include using a reference photodeteetor to receive an amount of the second excitation fight and output the reference measurement, the reference measurement may be indicative of the amount of the received second excitation light, and the amount of the received second excitation light may be indicative of the absorption of the interferent indicator.
- the method may further include using an interferent photodeteetor to receive second emission light emitted by the interferent indicator and output an interferent measurement indicative of an amount of the second emission light received by the interferent photodeteetor.
- the second emission light may vary in accordance with the effect on the analyte indicator.
- the method may further include using a first reference photodeteetor to receive an amount of the first excitation light and output a first reference measurement indicative of the amount of the received first excitation light.
- the effect on the analyte indicator may be calculated based at least on the reference measurement and the interferent measurement, in some aspects, the effect on the analyte indicator may be calculated based at least on a ratio of the interferent measurement and the reference measurement.
- the method may further include calculating an amount of blood in the medium.
- the conversion function may be adjusted based on at least the calculated effect on the analyte indicator and the calculated amount of blood in the medium.
- the reference measurement may be a second reference measurement, and using the analyte indicator to generate the analyte measurement may include: emitting first excitation light to the analyte indicator, using a first reference photodetector to receive an amount of the first, excitation light and output a first reference measurement indicative of the amount of the received first excitation light, and using a signal photodetector to receive first emission light emitted by the analyte indicator and output the analyte measurement.
- the analyte measurement may be indicative of the amount of the received first emission light.
- using the interferent indicator to generate the reference measurement may include: emitting second excitation light to the interferent indicator, and using the signal photodetector to receive an amount of the second excitation light and output the second reference measurement.
- the second reference measurement may be indicative of the amount, of the received second excitation light, and the amount of blood in the medium may be calculated based on at least the first and second reference measurements.
- the reference measurement may be a second reference measurement, and using the analyte indicator to generate the analyte measurement may include: emitting first excitation light to the analyte indicator, using a first reference photodetector to receive an amount of the first excitation light and output a first reference measurement indicative of the amount of the received first excitation light, and using a signal photodetector to receive first emission light emitted by the analyte indicator and output the analyte measurement.
- the analyte measurement may be indicative of the amount of the received first emission light.
- using the interferent indicator to generate the reference measurement may include: emitting second excitation light to the interferent indicator and using a second reference photodetector to receive an amount of the second excitation light and output the second reference measurement.
- the second reference measurement may be indicative of the amount of the received second excitation light.
- the amount of blood in the medium may be calculated based on at least the first and second reference measurements.
- the amount of blood in the medium may be calculated based on at least a ratio of the first and second reference measurements.
- the method may further include using an interferent photodetector to receive emission light emitted by the interferent indicator and output an interferent measurement indicative of an amount of the emission light received by the interferent photodetector, and the amount of blood in the medium may be calculated based on at least the interferent measurement.
- the system may include an indicator element including an analyte indicator and a degradation indicator.
- the analyte indicator may have a detectable property that varies in accordance with at least an amount or concentration of an analyte in a medium.
- the system may include a first light source configured to emit first excitation light to the analyte indicator.
- the system may include a second light source configured to emit, second excitation light to the degradation indicator.
- the system may include one or more photodetectors configured to (i) receive emission light emitted by the analyte indicator and output an analyte measurement indicative of an amount of emission light received by the one or more photodetectors and (ii) receive second excitation light reflected from the indicator element and output a reference measurement indicative of an amount of reflected second excitation light received by the one or more photodetectors.
- the reference measurement is indicative of an opacity of the indicator element.
- the system may include a controller configured to: (i) adjust a conversion function based on the reference measurement and (ii) calculate an analyte level using the adjusted conversion function and the analyte measurement.
- the one or more photodetectors may include a signal photodetector configured to (i) receive the first emission light and output the analyte measurement and (ii) receive the reflected second excitation light and output the reference measurement.
- the one or more photodetectors comprise (i) a signal photodetector configured to receive the first emission light and output the analyte measurement and (ii) a reference photodetector configured to receive the reflected second excitation light and output the reference measurement.
- the emission light may be first emission light
- the one or more photodetectors may be further configured to receive second emission light emitted by the degradation indicator and output a degradation measurement indicative of an amount of second emission light received by the one or more photodetectors
- the controller may be further configured to calculate an extent to which the analyte indicator has degraded based at least on the degradation measurement
- the controller may be configured to adjust the conversion function based on the reference measurement and the calculated extent to which the analyte indicator has degraded.
- FIG. 1 is a schematic view illustrating an analyte monitoring system embodying aspects of the present invention.
- FIGS. 2 A and 2B are schematic views each illustrating an analyte sensor embodying aspects of the present invention.
- FIG. 3 is a perspective view illustrating elements of an analyte sensor embodying aspects of the present invention.
- FIG. 4 is a schematic view 1 illustrating the layout of a semiconductor substrate of an analy te sensor embodying aspects of the present invention
- FIG. 5 is a chart illustrating non-limiting examples of sensitivity ratios correlating an analyte indicator to interferent indicators embodying aspects of the present invention.
- FIG. 6 is cross-sectional, perspective view of a transceiver embodying aspects of the invention.
- FIG. 7 is an exploded, perspective view of a transceiver embodying aspects of the invention.
- FIG. 8 is a schematic view illustrating a transceiver embodying aspects of the present invention.
- FIG. 9 is a flow chart illustrating a process for detecting and correcting for changes to an analyte indicator embodying aspects of the present invention .
- FIGS. 10-12 are schematic diagrams illustrating non-limiting examples of structures of indicator elements 106 embodying aspects of the present invention.
- FIG. 13 is a graph illustrating a correlation plot of the rates of interferent of the indicator and the reference dyes according to one non-limiting aspect of the invention.
- FIGS. 14A and 14B show fluori meter readings demonstrating decrease in fluorescence intensity of indicator molecule (excitation wavelength 380 nm) at 2 mM glucose and 50 uM hydrogen peroxide with simultaneous increase in the fluorescence intensity' of Compound A (excitation wavelength 470 nm) at a 1:1 ratio of indicator molecuie:Compound A demonstrating the use of Compound A as a copolymerizable reference dye.
- FIG. 15 A shows a non-limiting example of an analyte indicator molecule of the analyte indicator before and after degradation caused by reactive oxygen species (RGS) according to aspects of the present invention.
- FIG. 15B shows a non-limiting example of an interferent indicator molecule of the interferent indicator before and after degradation caused by ROS according to aspects of the present invention.
- FIGS. 16A and 16B illustrate the white color of an indicator element with no oxidation and the yellow color of the oxidized indicator element, respectively, for an indicator element including an interfered indicator embodying aspects of the present invention.
- FIG. 17A illustrates a decrease in the intensity or amount of light emitted by an analyte indicator over time according to aspects of the present invention.
- FIG, 17B illustrates an increase in the absorption of an indicator element over time and a decrease in the in tensity or amount of the second excitation light reflected by the indicator element over time according to aspects of the present invention.
- FIG. 18 is a graph illustrating experimental data from a clinical trial in which an analyte sensor 100 was implanted subcutaneously in the body of a living human
- FIG. 19A is a graph illustrating oxy-hemog!obin and de-oxy hemoglobin extinction coefficients at different wavelengths.
- FIG. 19B is a graph illustrating oxy-hemog!obin, de-oxy hemoglobin, methemoglobin, and bilirubin extinction coefficients at different wavelengths.
- FIG, 20 is a flow chart illustrating a process for detecting and correcting for an effect on an analyte indicator embodying aspects of the present invention.
- FIGS. 21 A and 21B show the chemical structures of the analyte indicator and interference indicator, respectively, according to some aspects.
- FIG. 22 shows an analyte sensor include multiple sensing areas and multiple indicator elements according to some aspects.
- FIG. 23 shows, as oxidation increases, the first emission light emitted by the analyte indicator decreasing and the second emission light emitted by the interferent indicator increasing with similar degradation kinetics according to some aspects.
- FIGS. 24A-24D show optical and fluorescence images of the analyte sensor after localized oxidation according to some aspects.
- FIGS. 25A-25D show in vivo measurements from the different sensing areas of the analyte sensor shown in FIG. 22 according to some aspects.
- FIG. 26A shows individual glucose concentrations calculated from sensing areas of the analyte sensor 100 shown in FIG. 22 individually according to some aspects
- FIG. 26B shows combined glucose concentrations calculated based on a weighted average of the individual glucose concentrations according to some aspects.
- FIG. 1 is a schematic view of an exemplary analyte monitoring system 50 embodying aspects of the present invention.
- the analyte monitoring system 50 may be a continuous analyte monitoring system (e.g., a continuous glucose monitoring system).
- the analyte monitoring system 50 may include one or more of an analyte sensor 100, a transceiver 101, and a display device 107.
- the analyte sensor 100 may be a small, fully subcutaneously implantable sensor that measures the amount or concentration of an analyte (e.g., glucose) in a medium (e.g., interstitial fluid) of a living animal (e.g., a living human).
- an analyte e.g., glucose
- the analyte sensor 100 may be a partially implantable (e.g,, transcutaneous) sensor or a fully external sensor.
- the transceiver 101 may be an externally worn transceiver (e.g., attached via an armband, waistband, waistband, or adhesive patch).
- the transceiver 101 may remotely power and/or communicate with the sensor 100 to initiate and receive the measurements (e.g., via near field communication (NFC)). However, this is not required, and, in some alternative aspects, the transceiver 101 may power and/or communicate with the analyte sensor 100 via one or more wired connections.
- NFC near field communication
- the transceiver 101 may be a smartphone (e.g., an NFC-enabled smartphone), in some aspects, the transceiver 101 may communicate information (e.g,, one or more analyte measurements) wirelessly (e.g,, via a BluetoothTM communication standard such as, for example and without limitation Bluetooth Low- Energy) to a hand held application running on a display device 107 (e.g., smartphone).
- information e.g, one or more analyte measurements
- a BluetoothTM communication standard such as, for example and without limitation Bluetooth Low- Energy
- FIG. 2A is a schematic view illustrating of an analyte sensor 100 embodying aspects of the present invention
- FIG. 3 is a perspective view 7 illustrating elements of an analyte sensor 100 embodying aspects of the present invention.
- the analyte sensor 100 may detect the presence, amount, and/or concentration of an analyte (e.g-., glucose, oxygen, cardiac markers, low-density lipoprotein (LDL), high-density lipoprotein (HDL), or triglycerides).
- the analyte sensor 100 may be optical sensors (e.g., fluorometers).
- the analyte sensor 100 may be chemical or biochemical sensors.
- the analyte sensor 100 may be a radio frequency identification (RFID) device. The analyte sensor 100 may be powered by a radio frequency (RF) signal from the transceiver 101
- RFID radio frequency identification
- the analyte sensor 100 may communicate with the transceiver 101.
- the transceiver 101 may be an electronic device that communicates with the analyte sensor 100 to power the analyte sensor 100 and/or receive measurement data (e.g., photodetector and/or temperature sensor readings) from the analyte sensor 100.
- the measurement data may include one or more readings from one or more photodetectors of the analyte sensor 100 and/or one or more readings from one or more temperature sensors of the analyte sensor 100.
- the transceiver 101 may calculate analyte concentrations from the measurement data received from the analyte sensor 100.
- the transceiver 101 may instead convey/relay the measurement data received from the analyte sensor 100 to another device (e.g., display device 107) for calculation of analyte concentrations.
- the analy te sensor 100 may perform the analyte concentration calculations and convey the calculated analyte concentrations to the transceiver 101.
- the transceiver 101 may implement a passive telemetry' for communicating with the implantable analyte sensor 100 via an inductive magnetic link for power and/or data transfer.
- the analyte sensor 100 may include an inductive element 114, which may be, for example, a ferrite based micro-antenna.
- the inductive element 114 may include a conductor 302 in the form of a coil and a magnetic core 304.
- the core 304 may be, for example and without limitation, a ferrite core
- the inductive element 114 may be connected to analyte detection circuitry of the analyte sensor 100.
- the inductive element 114 may be connected to micro- fluori meter circuitry (e.g., an application specification integrated circuit (ASIC)) and a related optical detection system of the analyte sensor 100.
- ASIC application specification integrated circuit
- the analyte sensor 100 may not include a battery', and, as a result, the analyte sensor 100 may rely on the transceiver 101 to provide power for the analyte sensor 100 of the sensor system 105 and a data link to convey analyte-related data from the analyte sensor 100 to transceiver 101.
- the analyte sensor 100 may include a battery.
- the analyte sensor 100 may he a passive, fully implantable multi site sensing system having a small size.
- the transceiver 101 may provide energy to run the analyte sensor 100 via a magnetic field.
- the magnetic transceiver-sensing system link can be considered as “weakly coupled transformer’ type.
- the magnetic transceiver-sensing system link may provide energy and a link for data transfer using amplitude modulation (AM). Although in some aspects, data transfer is carried out using AM, in alternative aspects, other types of modulation may be used.
- AM amplitude modulation
- the magnetic transceiver-sensor link may have a low efficiency of power transfer and, therefore, may require relatively high pow3 ⁇ 4r amplifier to energize the analyte sensor 100 at longer distances.
- the transceiver 101 and analyte sensor 100 may communicate using near field communication (e.g., at a frequency of 13,56MHz, which can achieve high penetration through the skin and is a medically approved frequency band) for power transfer.
- near field communication e.g., at a frequency of 13,56MHz, which can achieve high penetration through the skin and is a medically approved frequency band
- this is not required, and, in other aspects, different frequencies may be used for powering and communicating with the analyte sensor 100.
- the transceiver 101 may include an inductive element 103, such as, for example, a coil.
- the transceiver 101 may generate an electromagnetic wave or electrodynamic field (e.g., by using a coil 103) to induce a current in an inductive element 114 of the analyte sensor 100, which powers the analyte sensor 100.
- the transceiver 101 may also convey data (e.g, commands) to the analyte sensor 100.
- the transceiver 101 may convey data by modulating the electromagnetic wave used to power the analyte sensor 100 (e.g., by modulating the current flowing through a coil of the transceiver 101).
- the modulation in the electromagnetic wave generated by the transceiver 101 may be detected/extracted by the analyte sensor 100.
- the transceiver 101 may receive data (e.g,, measurement information) from the analyte sensor 100.
- the transceiver 101 may receive data by detecting modulations in the electromagnetic wave generated by the analyte sensor 100, e.g., by detecting modulations in the current flowing through the coil 103 of the transceiver 101.
- the analyte sensor 100 may include a sensor housing 102 (/. ⁇ ?., body, shell, capsule, or encasement), which may be rigid and biocompatible.
- the sensor housing 102 may be a silicon tube.
- the analyte sensor 100 may include a transmissive optical cavity.
- the transmissive optical cavity may be formed from a suitable, optically transmissive polymer material, such as, for example, acrylic polymers (e.g., polymethylmethacrylate (PMMA)).
- PMMA polymethylmethacrylate
- the analyte sensor 100 may include an Indicator element 106, such as, for example, a polymer graft or hydrogel coated, diffused, adhered, embedded, or grown on or in at least a portion of the exterior surface of the sensor housing 102.
- the sensor housing 102 may include one or more cutouts or recesses, and the indicator elements 106 may be located (partially or entirely) in the cutouts or recesses.
- the indicator element 106 may he porous and may allow the analyte (e.g., glucose) in a medium (e.g., interstitial fluid) to diffuse into the indicator element 106.
- the indicator element 106 e.g., polymer graft or hydrogel
- the indicator element 106 may include one or more of an analyte indicator 207 and an interferent indicator 209 (e.g., a degradation indicator).
- the analyte indicator 207 may exhibit one or more detectable properties (e.g., optical properties) that vary' in accordance with (i) the amount or concentration of the analyte in proximity to the indicator element 106 and (ii) an effect on the analyte indicator 207 (e.g., changes to the analyte indicator 207).
- the changes to the analyte indicator 207 may comprise the extent to which the analyte indicator 207 has degraded.
- the degradation may be (at least in part) ROS-induced oxidation.
- the analyte indicator 207 may include one or more analyte indicator molecules (e.g., fluorescent analyte indicator molecules), which may be distributed throughout the indicator element 106.
- the analyte indicator 207 may be a phenylboronic-based analyte indicator.
- the analyte sensor 100 may include a different analyte indicator, such as, for example and without limitation, glucose oxidase-based indicators, glucose dehydrogenase-based indicators, and glucose binding protein-based indicators.
- the interferent indicator 209 may exhibit one or more detectable properties (e.g, optical properties) that vary in accordance with changes to the interferent indicator 209.
- the interferent indicator 209 is not sensitive to the amount of concentration of the analyte in proximity to the indicator element 106. That is, in some aspects. the one or more detectable properties exhibited by the interferent indicator 209 do not vary in accordance with the amount or concentration of the analyte in proximity to the indicator element 106. However, this is not required, and, in some alternative aspects, the one or more detectable properties exhibited by the interferent indicator 209 may vary in accordance with the amount or concentration of the analyte in proximity to the indicator element 106.
- the changes to the interferent indicator 209 may comprise the extent to which the interferent indicator 209 has degraded.
- the degradation may be (at least in part) ROS-induced oxidation.
- the interferent indicator 209 may include one or more interferent indicator molecules (e.g, fluorescent interferent indicator molecules), which may be distributed throughout the indicator element 106.
- the interferent indicator 209 may be a phenylboronic-based interferent indicator.
- the analyte sensor 100 may include a different interferent indicator, such as, for example and without limitation, amp!ex red-based interferent indicators, dichlorodihydrofiuorescein-based indicators, dihydrorhodamine-based indicators, and scopo!etin-based interferent indicators.
- a different interferent indicator such as, for example and without limitation, amp!ex red-based interferent indicators, dichlorodihydrofiuorescein-based indicators, dihydrorhodamine-based indicators, and scopo!etin-based interferent indicators.
- an interferent indicator molecule may be a fluorescent probe compound having a wavelength of excitation between about 450 nm and about 550 nm, a Stokes shift between about 500 nm and about 650 nm, and a half-life of between about 50 days and about 150 days.
- an interferent indicator molecule may be a compound of formula I: wherein A”, B”, C”, A', B ⁇ C, W’, X, Y’, and Z’ represent -CH, wherein the hydrogen may optionally and independently be substituted with an alkyl group,
- Ri and R2 are independently selected from one or more vinyl groups, alkyl vinyl groups, acrylamide groups, methacrylamide groups, or other polymerizable groups.
- Exemplary and non-limiting compounds include the following:
- an interferent indicator molecule may include exemplary compounds such as the following:
- A, B’, C’, D ⁇ E, F, G, H ⁇ G, and J represent -CH, wherein the hydrogen may optionally and independently be substituted with an alkyl group.
- the molecules of the interferent indicator 209 may be a compound having a different formula having a wavelength of excitation between about 450 nm and about 550 nm, a Stokes shift between about 500 nm and about 650 nm, and a half-life of between about 50 days and about 150 days.
- the indicator element 106 may include one or more polymer backbones 1002.
- the polymer backbones 1002 may be polymer chains.
- the indicator element 106 may include one or more analyte indicator molecules A and one or more interferent indicator molecules D.
- the analyte indicator molecules A and interferent indicator molecules D may be monomers polymerized individually to a polymer backbone 1002.
- the indicator element 106 may include an equal number of analyte indicator molecules A and interferent indicator molecules D (see FIG.
- analyte indicator molecules A and interferent indicator molecules D see FIG. 11
- one or more interferent indicator molecules D may be chemically bonded to an analyte indicator molecule A (e.g., via a covalent bond), and the analyte indicator molecule A may be chemically bonded to a polymer backbone 1002.
- the analyte indicator molecules A and interferent indicator molecules D may be monomers, and the analyte indicator molecules A may be polymerized to the polymer backbone 1002.
- one or more analyte indicator molecules A may be chemically bonded to an interferent indicator molecules D, and the interferent indicator molecule D may be chemically bonded to a polymer backbone 1002.
- the analyte indicator molecules A and interferent indicator molecules D may be monomers, and the interferent indicator molecules D may be polymerized to the polymer backbone 1002.
- the analyte sensor 100 may measure changes to the analyte indicator 207 indirectly using the interferent indicator 209, which may by sensitive to degradation by reactive oxygen species (ROS) but not sensitive to the analyte.
- the interferent indicator 209 may have one or more optical properties that change with extent of oxidation and may be used as a reference dye for measuring and correcting for extent of oxidation of the analyte indicator.
- the extent to which the interferent indicator 209 has degraded may correspond to the extent to which the analyte indicator 207 has degraded.
- the extent to which the interferent indicator 209 has degraded may he proportional to the extent to which the analyte indicator 207 has degraded. In some non-limiting aspects, the extent to which the analyte indicator 207 has degraded may be calculated based on the extent to which the interferent indicator 209 has degraded. In some aspects, the analyte monitoring system 50 may correct, for changes in the analyte indicator 207 using an empiric correlation established through laboratory' testing.
- the analyte sensor 100 may include one or more first light sources 108 that emit first excitation light 329 over a range of wavelengths that interact with the analyte indicator 207 in the indicator element 106.
- the first excitation light 329 may be ultraviolet (UV) light.
- the analyte sensor 100 may include one or more light sources 227 that emit second excitation light 330 over a range of wavelengths that interact with the interferent indicator 209 in the indicator element 106.
- the second excitation light 330 may be blue light.
- the analyte sensor 100 may also include one or more photodetectors 224, 226, 228 (e.g, photodiodes, phototransistors, photoresist ors, or other photosensitive elements).
- photodetectors 224, 226, 228 e.g, photodiodes, phototransistors, photoresist ors, or other photosensitive elements.
- the analyte sensor 100 may include one or more signal photodetectors 224 sensitive to first emission light 331 (e.g., fluorescent light) emitted by the analyte indicator 207 of the indicator element 106 such that a signal generated by a photodetector 224 in response thereto that is indicative of the level of first emission light 331 of the analyte indicator 207 and, thus, the amount of analyte of interest (e.g., glucose).
- first emission light 331 e.g., fluorescent light
- the amount of analyte of interest e.g., glucose
- the analyte sensor 100 may include one or more reference photodetectors 226 may be sensitive to first excitation light 329 that may be reflected from the indicator element 106 such that a signal generated by a photodetector 226 in response thereto is indicative of the level of reflected first excitation light 329.
- the analyte sensor 100 may include one or more interferent photodetectors 228 sensitive to second emission light 332 (e.g., fluorescent light) emitted by the interferent indicator 209 of the indicator element 106 such that a signal generated by an in terferent photodetector 228 in response thereto that is indicative of the level of second emission light 332 of the interferent indicator 209 and, thus, the amount of degradation (e.g,, oxidation).
- the one or more signal photodetectors 224 may be sensitive to second excitation light 330 that may be reflected from the indicator element 106. In this wav, the one or more signal photodetectors 224 may act as reference photodetectors when the one or more light sources 227 are emitting second excitation light 330.
- the analyte sensor 100 may include one or more second reference photodetectors 230 that act as reference photodetectors when the one or more light sources 227 are emitting second excitation light 330.
- the one or more second reference photodetectors 230 may be sensitive to second excitation light 330 that may be reflected from the indicator element 106 such that a signal generated by a photodetector 230 in response thereto is indicative of the level of reflected second excitation light 330.
- the first excitation light 329 may be over a first wavelength range, and the second excitation light 330 over a second wavelength range, which may different than the first wavelength range.
- the first and second wavelength ranges do not overlap, but this not required, and, in some alternative aspects, the first and second wavelength ranges may overlap.
- the first emission light 331 may be over a third wavelength range
- the second emission light 332 may be over a fourth wavelength range, which may be different than the third wavelength range.
- the third and fourth wavelength ranges do not overlap, but this is not required, and, in some alternative aspects, the third and fourth wavelength ranges may overlap.
- the first and third wavelength ranges may be different.
- the first and third wavelength ranges do not overlap, but this is not required, and, in some alternative aspects, the first and third wavelength ranges may overlap.
- the second and fourth wavelength ranges may be different. In some non-limiting aspects, the second and fourth wavelength ranges do not overlap, but this is not required, and, in some alternative aspects, the second and fourth wavelength ranges may overlap. In some aspects, the second and third wavelength ranges may be different. In some non-limiting aspects, the second and third wavelength ranges may overlap, but this is not required and, in some alternative aspects, the second and third wavelength ranges do not overlap.
- one or more of the photodetectors 224, 226, 228, 230 may be covered by one or more filters that allow only a certain subset of wavelengths of light to pass through and reflect (or absorb) the remaining wavelengths.
- one or more filters on the one or more signal photodetectors 224 may allow only a subset of wavelengths corresponding to first emission light 331 and/or the reflected second excitation light 330.
- one or more filters on the one or more reference photodetectors 226 may allow only a subset of wavelengths corresponding to the reflected first excitation light 329.
- one or more filters on the one or more interferent photodetectors 228 may allow only a subset of wavelengths corresponding to second emission light 332.
- one or more filters on the one or more second reference photodetectors 230 may allow 7 only a subset of wavelengths corresponding to the reflected second excitation light 330.
- the interferent indicator 209 may be used as a reference dye for measuring and correcting for extent of oxidation of the analyte indicator 207.
- the analyte monitoring system 50 may correct for changes in the analyte indicator 207 using an empiric correlation established through laboratory 7 testing.
- FIG. 5 is a chart illustrating nonlimiting examples of sensitivity ratios correlating an analyte indicator 207 to an interferent indicator 209.
- the interferent indicator 209 may be more sensitive to oxidation than the analyte indicator 207.
- the interferent indicator 209 may be less sensitive to oxidation than the analyte indicator 207.
- the interferent indicator 209 and analyte indicator 207 may be equally sensitive to oxidation.
- the substrate 112 may be a circuit board (e.g., a printed circuit board (PCB) or flexible PCB) on which one or more of the circuit components 111 (e.g, analog and/or digital circuit components) may be mounted or otherwise attached.
- the substrate 112 may be a semiconductor substrate having one or more of the circuit components 111 fabricated therein.
- the fabricated circuit components may include analog and/or digital circuitry.
- the substrate 112 is a semiconductor substrate, in addition to the circuit components fabricated in the semiconductor substrate, circuit components may be mounted or otherwise attached to the semiconductor substrate.
- circuit components 111 which may include discrete circuit elements, an integrated circuit (e.g., an application specific integrated circuit (ASIC)) and/or other electronic components (e.g ⁇ ., a non-volatile memory), may be fabricated in the semiconductor substrate with the remainder of the circuit components 111 is secured to the semiconductor substrate, which may provide communication paths between the various secured components.
- ASIC application specific integrated circuit
- the analyte sensor 100 may include one or more light sources 108, 227, and one or more of the light sources 108, 227 may be mounted on or fabricated within in the substrate 112,
- the analyte sensor 100 may include one or more photodetectors 224, 226, 228, 230, and one or more of the photodetectors 224, 226, 228, 230 may be mounted on or fabricated in the substrate 112.
- one or more light sources 108, 227 may be mounted on the substrate 112, one or more photodetectors may be fabricated within the substrate 112, and all or a portion of the circuit components 111 may be fabricated within the substrate 112.
- the one or more of the indicator element 106, light source(s) 108, 227, photodetectors 224, 226, 228, 230, circuit components 111, and substrate 112 of the analyte sensor 100 may include some or all of the features described in one or more of U.S. Application Serial No, 13/761,839, filed on February 7, 2013, U.S, Application Serial No, 13/937,871, filed on July 9, 2013, U.S, Application Serial No. 13/650,016, filed on October 11, 2012, and U.S. Application Serial No. 14/142,017, filed on December 27, 2013, all of which are incorporated by reference in their entireties.
- the structure, function, and/or features of the sensor housing 102, analyte sensor 100, and/or transceiver 101 may be as described in one or more of U.S. Application Serial Nos. 13/761,839, 13/937,871, 13/650,016, and 14/142,017.
- the sensor housing 102 may have one or more hydrophobic, hydrophilic, opaque, and/or immune response blocking membranes or layers on the exterior thereof.
- the analyte sensor 100 may be a fully implantable sensor, this is not required, and, in some alternative aspects, the analyte sensor
- the analyte sensor 100 may be a transcutaneous sensing system having a wired connection to the transceiver 101.
- the analyte sensor 100 may be located in or on a transcutaneous needle (e.g., at the tip thereof).
- the analyte sensor 100 and transceiver instead of wirelessly communicating using inductive elements 103 and 114, the analyte sensor 100 and transceiver
- the analyte sensor 100 may be located in a catheter (e.g., for intravenous blood glucose monitoring) and may communicate (wirelessly or using wires) with the transceiver 101.
- the analyte sensor 100 may include a transceiver interface device.
- the transceiver interface device may include the antenna (e.g., inductive element 114) of the analyte sensor 100.
- the transceiver interface device may include the wired connection.
- FIGS. 6 and 7 are cross-sectional and exploded views, respectively, of a non-limiting aspect of the transceiver 101, which may be included in the analyte monitoring system 50 illustrated in FIG. 1,
- the transceiver 101 may include a graphic overlay 204, front housing 206, button 208, printed circuit board (PCB) assembly 210, battery' 212, gaskets 214, antenna 103, frame 218, reflection plate 216, back housing 220, ID label 222, and/or vibration motor 928.
- the vibration motor 928 may be attached to the front housing 206 or back housing 220 such that the battery 212 does not dampen the vibration of vibration motor 928.
- the transceiver electronics may be assembled using standard surface mount device (SMD) reflow and solder techniques.
- the electronics and peripherals may be put into a snap together housing design in which the front housing 206 and back housing 220 may be snapped together.
- the full assembly process may be performed at a single external electronics house. However, this is not required, and, in alternative aspects, the transceiver assembly process may be performed at one or more electronics houses, which may be internal, external, or a combination thereof.
- the assembled transceiver 101 may be programmed and functionally tested. In some aspects, assembled transceivers 101 may be packaged into their final shipping containers and be ready for sale.
- the antenna 103 may be contained within the housing 206 and 220 of the transceiver 101.
- the antenna 103 in the transceiver 101 may be small and/or flat so that the antenna 103 fits within the housing 206 and 220 of a small, lightweight transceiver 101.
- the antenna 103 may be robust and capable of resisting various impacts.
- the transceiver 101 may be suitable for placement, for example, on an abdomen area, upper-arm, wrist, or thigh of a patient body.
- the transceiver 101 may be suitable for attachment to a patient body by means of a biocompatible patch.
- the antenna 103 may be contained within the housing 206 and 220 of the transceiver 101, this is not required, and, in some alternative aspects, a portion or all of the antenna 103 may be located external to the transceiver housing.
- antenna 103 may wrap around a user’s wrist, arm, leg, or waist such as, for example, the antenna described in U.S. Patent No. 8,073,548, which is incorporated herein by reference in its entirety.
- FIG. 8 is a schematic view 7 of an external transceiver 101 according to a non-limiting aspect.
- the transceiver 101 may have a connector 902, such as, for example, a Micro-Universal Serial Bus (USB) connector.
- the connector 902 may enable a wired connection to an external device, such as a personal computer (e.g., personal computer 109) or a display device 107 (e.g,, a smartphone).
- a personal computer e.g., personal computer 109
- a display device 107 e.g, a smartphone
- the transceiver 101 may exchange data to and from the external device through the connector 902 and/or may receive power through the connector 902.
- the transceiver 101 may include a connector integrated circuit (IC) 904, such as, for example, a USB-iC, which may control transmission and receipt of data through the connector 902.
- the transceiver 101 may also include a charger IC 906, which may receive power via the connector 902 and charge a battery 908 (e.g., lithium-polymer battery).
- the batten, ' 908 may be rechargeable, may have a short recharge duration, and/or may have a small size.
- the transceiver 101 may include one or more connectors in addition to (or as an alternative to) Micro-USB connector 904.
- the transceiver 101 may include a spring-based connector (e.g, Pogo pin connector) in addition to (or as an alternative to) Micro-USB connector 904, and the transceiver 101 may use a connection established via the spring-based connector for wired communication to a personal computer (e.g, personal computer 109) or a display device 107 (e.g, a smartphone) and/or to receive power, which may be used, for example, to charge the battery' 908.
- a personal computer e.g, personal computer 109
- a display device 107 e.g, a smartphone
- the transceiver 101 may have a wireless communication IC 910, which enables wireless communication with an external device, such as, for example, one or more personal computers (e.g, personal computer 109) or one or more display devices 107 (e.g, a smartphone).
- the wireless communication IC 910 may employ one or more wireless communication standards to wirelessly transmit data.
- the wireless communication standard employed may he any suitable wireless communication standard, such as an ANT standard, a Bluetooth standard, or a Bluetooth Low Energy (BLE) standard (e.g,
- the wireless communication IC 910 may be configured to wirelessly transmit data at a frequency greater than 1 gigahertz (e.g, 2,4 or 5 GHz).
- the wireless communication IC 910 may include an antenna (e.g, a Bluetooth antenna).
- the antenna of the wireless communication IC 910 may be entirely contained within the housing (e.g, housing 206 and 220) of the transceiver 101. However, this is not required, and, in alternative aspects, all or a portion of the antenna of the wireless communication IC 910 may be external to the transceiver housing.
- the transceiver 101 may include a display interface device, which may enable communication by the transceiver 101 with one or more display devices 107.
- the display interface device may include the antenna of the wireless communication IC 910 and/or the connector 902.
- the display interface device may additionally include the wireless communication IC 910 and/or the connector IC 904.
- the transceiver 101 may include voltage regulators 912 and/or a voltage booster 914.
- the battery 908 may supply power (via voltage booster 914) to radio- frequency identification (RFID) reader IC 916, which uses the inductive element 103 to convey information (e.g ,, commands) to the sensor 101 and receive information (e.g ., measurement information) from the sensor 100.
- RFID radio- frequency identification
- the sensor 100 and transceiver 101 may communicate using near field communication (NFC) (e.g ⁇ ., at a frequency of 13.56 MHz).
- NFC near field communication
- the inductive element 103 is a fiat antenna.
- the antenna may be flexible.
- the inductive element 103 of the transceiver 101 may be in any configuration that permits adequate field strength to be achieved when brought within adequate physical proximity to the inductive element 114 of the sensor 100.
- the transceiver 101 may include a power amplifier 918 to amplify the signal to be conveyed by the inductive element 103 to the sensor 100.
- the transceiver 101 may include a peripheral interface controller (PIC) controller 920 and memory 922 ⁇ e.g.. Flash memory), which may be non-volatile and/or capable of being electronically erased and/or rewritten.
- PIC controller 920 may control the overall operation of the transceiver 101.
- the PIC controller 920 may control the connector IC 904 or wireless communication I € 910 to transmit data via wired or wireless communication and/or control the RFID reader IC 916 to convey data via the inductive element 103.
- the PIC controller 920 may also control processing of data received via the inductive element 103, connector 902, or wireless communication IC 910.
- the transceiver 101 may include a sensor interface device, which may enable communication by the transceiver 101 with a sensor 100.
- the sensor interface device may include the inductive element 103.
- the sensor interface device may additionally include the RFID reader IC 916 and/or the power amplifier 918.
- the sensor interface device may include the wired connection.
- the transceiver 101 may include a display 924 (e.g, liquid crystal display and/or one or more light emitting diodes), which PIC controller 920 may control to display data (e.g., analyte concentration values).
- the transceiver 101 may include a speaker 926 (e.g ⁇ ., a beeper) and/or vibration motor 928, which may be activated, for example, in the event that an alarm condition (e.g, detection of a hypoglycemic or hyperglycemic condition) is met.
- the transceiver 101 may also include one or more additional sensors 930, which may include an accelerometer and/or temperature sensor that may be used in the processing performed by the PIC controller 920.
- FIG. 9 illustrates non-limiting aspect of an analyte monitoring process 950 that may be performed by the analyte monitoring system 50.
- the process 950 may detect and correct for an effect on the analyte indicator 207.
- the process 950 may include a step 952 in which the analyte monitoring system 50 measures an analyte signal.
- the step 952 may include the transceiver 101 conveying an analyte measurement command to the analyte sensor 100.
- the step 952 may include the analyte sensor 100, in response to receiving and decoding the analyte measurement command, using the first light source 108 to emit first excitation light 329 to the indicator element 106.
- the analyte indicator 207 of the indicator element 106 may receive the first excitation light 329 and emit first emission light 331.
- the signal photodetector 224 may receive the first emission light 331 and generate an analyte measurement signal based on the amount of first emission light 331 received by the signal photodetector 224.
- the step 952 may include the analyte sensor 100 using the reference photodetector 226 to receive first excitation light 329 that was reflected from the indicator element 106 and generate a reference signal indicative of the amount of reflected first excitation light 329 received by the reference photodetector 226.
- the process 950 may include a step 954 in which the analyte monitoring system 50 measures an interferent signal.
- the step 954 may include the transceiver 101 conveying an interferent measurement command to the analyte sensor 100.
- the step 954 may include the analyte sensor 100, in response to receiving and decoding the interferent measurement command, using the second light source 227 to emit second excitation light 330 to the indicator element 106,
- the interferent indicator 209 of the indicator element 106 may receive the second excitation light 330 and emit second emission light 332.
- the interferent photodetector 228 may receive the second emission light 332 and generate an interferent measurement signal based on the amount of second emission light 332 received by the interferent photodetector 228.
- the step 954 may include the analyte sensor 100 using the signal photodetector 224 (and/or the second reference photodetector 230) to receive second excitation light 330 that was reflected from the indicator element 106 and generate a reference signal indicative of the amount of reflected second excitation light 330 received by the signal photodetector 224 (and/or the second reference photodetector 230).
- the step 954 may not include conveying an interferent measurement command to the analyte sensor 100, and the analyte sensor 100 may use the second light source 227 to emit the second excitation light 330 to the indicator element 106 in response to receiving and decoding an analyte measurement command (instead of in response to receiving and decoding a separate interferent measurement command).
- steps 952 and 954 may be performed simultaneously, and the analyte sensor 100 may use the first and second light sources 108, 227 to emit simultaneously the first and second excitation lights 329, 330 to the indicator element 106.
- step 954 may he performed before step 952.
- the process 950 may include a step 956 in which the analyte monitoring system 50 calculates changes in the analyte indicator 207.
- the step 956 may include the transceiver 101 receiving sensor data from the analyte sensor 100.
- the sensor data may include one or more of an analyte measurement, a first reference measurement, an interferent measurement, a second reference measurement, and a temperature measurement.
- the analyte measurement may correspond to the amount of first emission light 331 received by the signal photodetector 224
- the first reference measurement may correspond to the amount of reflected first excitation light 329 received by the reference photodetector 226
- the interferent measurement may correspond to the amount of second emission light 332 received by the interferent photodetector 228, and the second reference measurement may correspond to the amount of reflected second excitation light 330 received by the signal photodetector 224.
- one or more of the analyte measurement and the first reference measurement may he received during step 952, and one or more of the interferent measurement and the second reference measurement may be received during step 954.
- the step 956 may include the transceiver 101 (e.g., the microcontroller 910 of the transceiver 101) determining the extent that the analyte indicator 207 has degraded based at least on the received interferent measurement.
- the step 956 may include the transceiver 101 determining (i) the extent that the interferent indicator 209 has been degraded based on the received interferent measurement and (ii) the extent that the analyte indicator 207 has been degraded based on the determined extent to which the interferent indicator 209 has been degraded.
- the transceiver 101 may additionally or alternatively use one or more previous interferent measurements and/or one or more previous determinations of the extent to which the interferent indicator 209 has degraded to determine the extent to which the analyte indicator 207 has degraded.
- the process 950 may include a step 958 in which the analyte monitoring system 50 corrects for the calculated changes to the analyte indicator 207 and/or the calculated amount of blood in the iSF.
- the transceiver 101 may correct for the calculated changes to the analyte indicator 207 and/or the calculated amount of blood in the ISF by adjusting a conversion function used to calculate an analyte level based on an analyte measurement.
- adjusting the conversion function may include adjusting one or more parameters of the conversion function.
- the transceiver 101 may additionally or alternatively adjust the conversion function based on the first reference measurement, which may be indicative of in-vivo hydration of the indicator element 106 and/or wound healing kinetics.
- the transceiver 101 may additionally or alternatively adjust the conversion function based on the second reference measurement, which may be a measurement of the opacity of the indicator element 106 in the wavelength range of the first emission light 331.
- the process 950 may include a step 960 in which the analyte monitoring system 50 calculates an analyte level (e.g., an analyte concentration).
- the transceiver 101 e.g., the microcontroller 910 of the transceiver 101
- the transceiver 101 may calculate the analyte level using at least the adjusted conversion function and the analyte measurement.
- the transceiver 101 may additionally use the temperature measurement to calculate the analyte level.
- the process 950 may include a step 962 in which the analyte monitoring system 50 displays the calculated analyte level.
- the transceiver 101 may display the analyte level on the display 924.
- the transceiver 101 may additionally or alternatively convey the calculated analyte level to the display device 107, and the display device 107 may additionally or alternatively convey the calculated analyte level.
- Compound A was copolymerized with an indicator molecule onto a hydrogel. Methods of copolymerizing are described in U.S. Pat. Nos. 7,060,503 (Colvin) and 9,778,190 (Huffstetler et al.), which are incorporated by reference in their entireties.
- TFM has a chemical name of 9- [N- [6-(4,4,5 ,5 ,-tetramethy! ⁇ 1 ,3 , 2-di oxaborolano)-3 - (trifluoromethyi)benzyl] -N- [3 - (methacrylamido)propylamino]metliyl]- 10-[N-[6-(4,4,5 ,5 letrametliyl- 1 ,3 ,2-di oxaborolano)-3 - (trifluoromethyi)benzyl] ⁇ N-[2 ⁇
- samples were explan ted, they were washed and disinfected using ENZQL ⁇ enzymatic detergent and glutaraldehyde solution. The explanted samples were then analyzed by fluorimetry to evaluate fluorescence intensity change in Compound A and to correlate % increase in Compound A intensity to % modulation loss in the indicator.
- the intensity or amount of emission light (e g., first emission light
- FIG. 15 A shows a non-limiting example of an analyte indicator molecule of the analyte indicator 207 before and after degradation caused by reactive oxygen species (RQS).
- the intensity or amount of emission light e.g., first emission light 331 emitted by an analyte indicator 207 including the analyte indicator molecule shown in FIG. 15 A may decrease as degradation of the analyte indicator 207 increases over time.
- the intensity or amount of emission light (e.g., second emission light
- the interferent indicator 209 may change (e.g., increase or decrease) as degradation of the interferent indicator 209 increases.
- the extent of the degradation of the interferent indicator 209 may correspond to the extent of degradation of the analyte indicator 207.
- the extent of the change in the intensity or amount of emission light emitted by the interferent indicator 209 may correspond to the change in the intensity or amount of emission light emitted by the analyte indicator 207.
- FIG. 15B shows a non-limiting example of an interferent indicator molecule of the interferent indicator 209 before and after degradation caused by ROS. In some aspects, as shown in FIG.
- the intensity or amount of emission light (e.g., second emission light 332) emitted by an interferent indicator 209 including the analyte indicator molecule shown in FIG. 15B may increase as degradation of the interferent indicator 209 increases over time. However, this is not required, and, in some alternative aspects, the intensity or amount of emission light (e.g., second emission light 332) emitted by an interferent indicator 209 may decrease as degradation of the interferent indicator 209 increases over time.
- the absorption of the interferent indicator 209 may change (e.g., increase or decrease) as degradation of the interferent indicator 209 increases.
- the extent of the degradation of the interferent indicator 209 may correspond to the extent of degradation of the analyte indicator 207.
- the extent of the change in the absorption of the interferent indicator 209 may correspond to the change in the intensity or amount of emission light emitted by the analyte indicator 207.
- the color of the interferent indicator 209 may change.
- the color of the indicator element 106 may change from white with no oxidation, as shown in FIG. 16 A, to yellow when oxidized, as shown in FIG, 16B.
- a change from white to yellow is not required, and, in some alternative aspects, different color changes may occur with degradation (e.g., white to yellow, white to orange, yellow 7 to red, orange to browm, etc.).
- the change in the color of the interferent indicator 209 may change the absorption of the interferent indicator 209 (and, therefore, the absorption of the indicator element 106 including the interferent indicator 209).
- the intensity or amount of the emission light 331 emitted by the analyte indicator 207 may decrease over time (e.g., as degradation, such as oxidation, of the analyte indicator 207 increases).
- the absorption of the indicator element 106 may increase overtime (e.g., as degradation, such as oxidation, of the interferent indicator 209 increases).
- the intensity or amount of the second excitation light 330 reflected by the indicator element 106 may decrease over time (e.g., as degradation, such as oxidation, of the interferent indicator 209 increases).
- the increase in the absorption of the indicator element 106 and the decrease in the intensity or amount of the second excitation light 330 reflected by the indicator element 106 may correspond to the decrease in the intensity or amount of emission light 331 emitted by the analyte indicator 207.
- FIG. 18 illustrates a graph with experimental data from a clinical trial in which an analyte sensor 100 was implanted subcutaneously in the body of a living human.
- the glucose signal area of FIG. 18 illustrates analyte measurements indicative of amounts of the first emission light 331 emitted by the analyte indicator 207 and received by the one or more signal photodetectors 224 over time.
- the analyte measurements may fluctuate initially (e.g., during a wound healing period after implantation of the analyte sensor 100 when there may be an increased amount of blood in the interstitial fluid in proximity to the sensor 100).
- the analyte measurements may then decrease over time due to an increase of an effect on the analyte indicator 207 (e.g., degradation of the analyte indicator 207),
- the UV reference area of FIG. 18 illustrates first reference measurements indicative of amounts of first excitation light 329 reflected by the indicator element 106 and received by the one or more first reference photodetectors 226 over time.
- the first reference measurements may fluctuate initially (e.g., during a wound healing period after implantation of the analyte sensor 100 when there may be an increased amount of blood in the interstitial fluid in proximity to the sensor 100).
- the yellow oxidation indicator (YOI) area of FIG. 18 illustrates interferent measurements indicative of amounts of second emission light 332 emitted by the interferent indicator 209 and received by the one or more interferent photodetectors 228.
- the interferent measurements rvere cut off starting on day 10 but were expected to increase over time as degradation of the interferent indicator 209 increased.
- experimental data from in vitro oxidation studies have demonstrated an increase in the intensity or amount of the light emitted by the interferent indicator 209 over time as degradation of the interferent. indicator 209 increased.
- the blue reference area of FIG. 18 illustrates second reference measurements indicative of amounts of second excitation light 330 reflected by the indicator element 106 and received by one or more photodetectors (e.g., the one or more signal photodetectors 224 of FIG. 2A or the one or more second reference photodetectors 230 of FIG. 2B) over time.
- the second reference measurements may fluctuate initially (e.g., during a wound healing period after implantation of the analyte sensor 100 when there may be an increased amount of blood in the interstitial fluid in proximity to the sensor 100).
- the second reference measurements may then decrease over time as the absorption of the interferent indicator 209 (and therefore the absorption of the indicator element 106 that includes the interferent indicator 209) increases (e.g., due to degradation, such as oxidation, of the interferent indicator 209).
- the decrease of the second reference measurements over time corresponds to the decrease of the analyte measurements over time.
- the experimental data confirms that measurements of the absorption of an indicator element 106 including the interferent indicator 209 can be used to calculate an effect on (e.g., degradation of) the analyte indicator 207 of the indicator element 106.
- FIG. 20 illustrates non-limiting aspect of a process 2000 that may be performed by the analyte monitoring system 50.
- the process 2000 may detect and correct for an effect on the analyte indicator 207.
- the process 2000 may additionally or alternatively detect and correct for blood in the medium (e.g., interstitial fluid) in proximity to the analyte indicator 207.
- the medium e.g., interstitial fluid
- the process 2000 may include a step 2002 in which the analyte monitoring system 50 performs an analyte measurement.
- step 2002 may include the analyte monitoring system 50 (e.g., the analyte sensor 100) using an analyte indicator 207 to generate an analyte measurement indicative of an amount or concentration of an analyte in a medium.
- the analyte measurement may vary? in accordance with at least an effect on the analyte indicator 207.
- the effect on the analyte indicator 207 may be degradation of the analyte indicator 207.
- the degradation may be include oxidation-induced degradation, such as, for example, degradation by reactive oxygen species (ROS).
- ROS reactive oxygen species
- using the analyte indicator 207 to generate the analyte measurement in step 2002 may include using one or more first light sources 108 to emit first excitation light 329 to the analyte indicator 207 and using a signal photodetector 224 configured to receive first emission light 331 emitted by the analyte indicator 207 and output the analyte measurement.
- the analyte measurement may be indicative of an amount of the first emission light 331 received by the signal photodetector 224.
- the step 2002 may include the analyte monitoring system 50 (e.g., the analyte sensor 100) using one or more first reference photodetectors 226 to receive an amount of the first excitation light 329 and output a first reference measurement indicative of the amount of the received first excitation light 329,
- the first excitation light 329 received by the first reference photodetector 226 may have been emitted by the one or more first light sources 108 and reflected from the first analyte indicator 207).
- the step 2002 may include the transceiver 101 conveying and the analyte sensor 100 receiving an analyte measurement command.
- the step 2002 may include the analyte sensor 100, in response to receiving and decoding the analyte measurement command, using the first light source 108 to emit first excitation light 329 to the indicator element 106.
- the analyte indicator 207 of the indicator element 106 may receive the first excitation light 329 and emit first emission light 331.
- the signal photodetector 224 may receive the first emission light 331 and generate the analyte measurement signal based on the amount of first emission light 331 received by the signal photodetector 224.
- the reference photodetector 226 may receive first excitation light 329 that was reflected from the indicator element 106 and generate first reference measurement.
- the process 2000 may include a step 2004 in which the analyte monitoring system 50 measures an effect on the analyte indicator 207.
- the step 2004 may include the analyte monitoring system 50 (e.g., the analyte sensor 100) using an interferent indicator 209 to generate a second reference measurement.
- the second reference measurement may be indicative of an absorption of the interferent indicator 209.
- the absorption of the interferent indicator 209 may vary in accordance with the effect on (e.g., degradation of) the analyte indicator 207.
- the second reference measurement generated in step 2004 may be in addition to the first reference measurement, which may be generated in step 2002 and may be indicative of the amount of first excitation light 329 received by the one or more first reference photodetectors 226). However, the second reference measurement may be generated in step 2004 even in aspects in which the first reference measurement is not generated in step 2002.
- using the interferent indicator 209 to generate the second reference measurement in step 2004 may include using one or more second lights sources 227 to emit second excitation light 330 to the interferent indicator 209.
- using the interferent indicator 209 to generate the second reference measurement may include using one or more photodetectors (e.g., one or more signal photodetectors 224 as shown in FIG. 2 A or one or more second reference photodetectors 230 as shown in FIG, 2B) to receive an amount of the second excitation light 330 and output the second reference measurement.
- the second reference measurement may be indicative of the amount of the received second excitation light 330, and the amount of the received second excitation light 330 may be indicative of the absorption of the interferent indicator 209.
- the step 2004 may include (in addition or as an alternative to generating the second reference measurement) the analyte monitoring system 50 (e.g,, the analyte sensor 100) using the interferent indicator 209 to generate an interferent measurement.
- generating an interferent measurement may include using one or more second lights sources 227 to emit second excitation light 330 to the interferent indicator 209.
- generating an interferent measurement may include using an interferent photodetector 228 to receive second emission light 332 emitted by the interferent indicator 209 and output an interferent measurement indicative of an amount of the second emission light 332 received by the interferent photodetector 228.
- the second emission light 332 may vary' in accordance with the effect on (e.g., degradation of) the analyte indicator 331.
- the step 2004 may include the transceiver 101 conveying and the analyte sensor 100 receiving an interferent measurement command.
- the step 2004 may include the analyte sensor 100, in response to receiving and decoding the interferent measurement command, measures the effect on the analyte indicator 207.
- measuring the effect on the analyte indicator may include using the second light source 227 to emit second excitation light 330 to the indicator element 106.
- the interferent indicator 209 of the indicator element 106 may receive the second excitation light 330 and emit second emission light 332.
- the interferent photodetector 228 may receive the second emission light 332 and generate the interferent measurement signal based on the amount of second emission light 332 received by the interferent photodetector 228,
- the signal photodetector 224 (and/or the second reference photodetector 230) may receive second excitation light 330 that was reflected from the indicator element 106 and generate the second reference signal.
- the step 2004 may not include the transceiver 101 conveying and the analyte sensor 100 receiving an interferent measurement command, and the analyte sensor 100 may measures the effect on the analyte indicator 207 in response to receiving and decoding an analyte measurement command (instead of in response to receiving and decoding an interferent measurement command).
- step 2002 may be performed before step 2004.
- steps 2002 and 2004 may be performed simultaneously, and the analyte sensor 100 may use the first and second light sources 108, 227 to emit simultaneously the first and second excitation lights 329, 330 to the indicator element 106.
- step 2004 may be performed before step 2002.
- the process 2000 may include a step 2006 in which the analyte monitoring system 50 (e.g., the transceiver 101) calculates the effect on the analyte indicator 207 (e.g., the extent to which the analyte indicator 207 has degraded).
- the step 2006 may include the analyte sensor 100 conveying and the transceiver 101 receiving sensor data.
- the sensor data may include one or more of the analyte measurement, the first reference measurement, the interferent measurement, the second reference measurement, and a temperature measurement.
- the step 2002 may include the analyte sensor 100 conveying and the transceiver 101 receiving sensor data (e.g., the analyte measurement, the first reference measurement, and/or the temperature measurement), and/or the step 2004 may include the analyte sensor 100 conveying and the transceiver 101 receiving sensor data (e.g., the interferent measurement and/or the second reference measurement),
- sensor data e.g., the analyte measurement, the first reference measurement, and/or the temperature measurement
- the step 2004 may include the analyte sensor 100 conveying and the transceiver 101 receiving sensor data (e.g., the interferent measurement and/or the second reference measurement)
- the analyte monitoring system 50 may calculate the effect on the analyte indicator 207 in step 2006 based at least on one or more measurements generated in step 2004 (e.g., the second reference measurement indicative of the absorption of the interferent indicator 209 and/or the interferent measurement indicative of the emission of the interferent indicator 209).
- the system 50 may calculate the effect on the analyte indicator 106 based on a change in the absorption of the analyte indicator 106, which may be indicated by the second reference measurement.
- the system 50 may calculate the effect on the analyte indicator 207 based on a ratio of the interferent measurement and the second reference measurement.
- the step 2006 may additionally or alternatively include the system 50 using one or more previous interferent measurements and/or one or more previous calculations of the effect on the analyte indicator 207 to calculate the effect (e.g., the current effect) on the analyte indicator 207.
- the process 2000 may include a step 2008 in which the analyte monitoring system 50 (e.g., the transceiver 101) calculates an amount of blood in the medium (e.g., interstitial fluid (ISF)).
- the amount of blood in the medium may be calculated in step 2008 based on the second reference measurement, which may be indicative of an amount of received second excitation light 330.
- the second reference measurement may be indicative of an absorption of the interferent indicator 209.
- the amount of blood in the medium may additionally or alternatively be calculated based on the first reference measurement, which may be indicative of the amount of received first excitation light 329.
- the amount of blood in the medium may be calculated in step 2008 based on at least a ratio of the first and second reference measurements. In some aspects, the amount of blood in the medium may additionally or alternatively be calculated in step 2008 based on the interferent measurement, which may be indicative of the amount of received second emission light 332.
- FIG, 19A is a graph illustrating oxy-hemoglobin (FIbCfi) and de-oxy hemoglobin (Fib) extinction coefficients at different wavelengths.
- FIG. 19B is a graph illustrating oxy-hemoglobin (HbCh), de-oxy hemoglobin (Hb), methemoglobin (MetHh), and bilirubin extinction coefficients at different wavelengths.
- the system 50 may use the known extinction coeffi cients of one or more of oxy-hemoglobin (FlbCb), de-oxy hemoglobin (Hb), methemoglobin (MetHb), and bilirubin at the wavelengths of one or more of the first excitation light 329 (e.g., 380 nm) and the second excitation light 330 (e g., 470 nm) along with one or more of the first and second reference measurements to calculate the amount of blood in the medium in proximity to the analyte sensor 100.
- FlbCb oxy-hemoglobin
- Hb de-oxy hemoglobin
- MetHb methemoglobin
- bilirubin at the wavelengths of one or more of the first excitation light 329 (e.g., 380 nm) and the second excitation light 330 (e g., 470 nm) along with one or more of the first and second reference measurements to calculate the amount of blood in the medium in proximity to
- the process 2000 may include a step 2010 in wliich the analyte monitoring system 50 (e.g., the transceiver 101) corrects for an effect on the analyte indicator 207 and/or blood in the medium (e.g., ISF).
- the step 2010 may include the analyte monitoring system 50 (e.g., the transceiver 101) adjusting a conversion function.
- the conversion function may be used to calculate an analyte level based on the analyte measurement.
- the conversion function may be adjusted in step 2010 based on the calculated effect on the analyte indicator 207 (e.g., calculated in step 2006).
- the conversion function may additionally or alternatively be adjusted in step 2010 based on the calculated blood in the medium (e.g., calculated in step 2008).
- adjusting the conversion function may include adjusting one or more parameters of the conversion function.
- the process 2000 may include a step 2012 in which the analyte monitoring system 50 (e.g., the transceiver 101) calculates an analyte level (e.g., an analyte concentration).
- the step 2012 may include the analyte monitoring system 50 (e.g., the transceiver 101) using the adjusted conversion function and the analyte measurement.
- the system 50 may additionally use the temperature measurement to calculate the analyte level.
- the process 2000 may include a step 2014 in which the analyte monitoring system 50 displays the calculated analyte level.
- the system 50 may display the analyte level on the display 924.
- the system 50 may additionally or alternatively convey the calculated analyte level to the display device 107, and the display device 107 may additionally or alternatively convey the calculated analyte level.
- the analyte sensor 100 of the analyte monitoring system 50 may be a fully implantable sensor and may utilize a fluorescent, boronic acid glucose-binding moiety as the analyte indicator 207 for the measurement of glucose.
- the binding affinity of this analyte indicator 207 may be specific for glucose but may also be susceptible to oxidative de-boronation through localized Reactive Oxygen Species (ROS) (e.g., hydrogen peroxide (H2Q2)) present in the interstitial space.
- ROS Reactive Oxygen Species
- the analyte sensor 100 may rely on calibration updates to characterize the rate of oxidation from localized in vivo concentrations of RGS.
- utilizing the indicator element 106 that includes the interferent indicator 209 to measure ROS concentration may enable reduction of the calibration frequency
- the analyte sensor 100 may include multiple sensing areas 2202 (e g., sensing areas 2202a, 2202b, 2202c, and 2202d).
- the sensing areas 2202 may each include a measurement electronics (e.g., optical measurement electronics).
- the measurement electronics in each of the sensing areas 2202 may include one or more light sources (e.g., a light sources 108 and 227) and/or one or more photodetectors (e.g., photodetectors 224, 226, 228, and/or 230).
- the analyte sensor 100 may include first and second substrates 112, sensing areas 2202a and 2202c may he on the first substrate 112, and sensing areas 2202b and 22Q2d may be on the second substrate 112.
- the sensing areas 2202a and 2202c may be long end distal (LED) and long end central (LEG) sensing areas of the analyte sensor 100, respectively, and the sensing areas 2202b and 2202d may be short end central (SEC) and short end distal (SED) sensing areas of the analyte sensor, respectively.
- the analyte sensor 100 may include one or more indicator elements 106 (e.g., indicator elements 106a and 106b), which may be, for example, one or more hydrogels on the sensor housing 102.
- the one or more indicator elements 106 may each include an analyte indicator 207 and an interferent indicator 209.
- the analyte sensor 100 may use the analyte indicator 207 to measure the presence, amount, and/or concentration of an analyte ⁇ e.g., glucose, oxygen, cardiac markers, low-density lipoprotein (LDL), high-density lipoprotein (HDL), or triglycerides).
- the analyte sensor 100 may use the interferent indicator 209 to measure RQS induced signal degradation.
- the analyte indicator 207 and the interferent indicator 209 may be copolymerized into a single biocompatible hydrogel.
- the analyte indicator 207 and the interferent indicator 209 may have negligible spectral overlap and undergo similar degradation (e.g., similar degradation of boronie acids) in vivo.
- the analyte indicator 207 of the one or more indicator elements 106 may be, for example, TFM. In some aspects, the analyte indicator 207 may have the chemical structure shown in FIG. 21A. In some aspects, as shown in FIG.
- an analyte e.g., glucose
- the analyte indicator 207 to which the analyte is bound may emit first emission light 331 (e.g., fluorescent light) when irradiated by the first excitation light 329
- the analyte indicator 207 to which the analyte Is not hound may not emit light (or emit only a small amount of light) when irradiated by the first excitation light 329.
- first emission light 331 e.g., fluorescent light
- the analyte indicator 207 to which the analyte Is not hound may not emit light (or emit only a small amount of light) when irradiated by the first excitation light 329.
- oxidation of the interferent indicator 209 cause the interferent indicator 209 to emit second emission light 332 (e.g., when irradiated by the second excitation light. 330).
- oxidation of the interferent indicator 209 may additionally or alternatively cause the absorption of the interferent indicator 209 (e.g., absorption of the second excitation light 330 by the interferent indicator 209) to change.
- absorption of the interferent indicator 209 e.g., absorption of the second excitation light 330 by the interferent indicator 209
- one or more sensing areas 2202 may interact with (e.g., emit first and second excitation lights 329 and 330 to and measure first and second emission lights 331 and 332 emitted by) a first indicator element 106a, and one or more different sensing areas 2202 (e.g., sensing areas 2202b and 2202d) may interact with a second indicator element 106b.
- the analyte sensor 100 may be configured to measure in vivo signal degradation and signal changes resulting from RQS, which may reduce the frequency with which calibration based on reference analyte measurements (e.g., finger stick blood glucose measurements).
- the analyte sensor 100 may sense an analyte (e.g., glucose) in each of the multiple sensing areas 2202 (e.g., each of the sensing areas 2202a-2022d).
- the multiple sensing areas 2202 may be redundant sensing areas.
- the analyte indicator 207 may be excited by first excitation light 329 emitted by a light source 108 (e.g., a UV LED), and the interferent indicator 209 may be excited by second excitation light 330 emitted by a light source 227 (e.g., a blue LED).
- the first excitation light 329 and the first emission light 331 emitted by the analyte indicator 207 may be measured by one or more first reference photodetectors 226 (e.g., one or more UV filter coated photodiodes) and one or more signal photodetectors 224 (e.g., one or more blue filter coated photodiodes) respectively.
- the second excitation light 330 may be measured by one or more signal photodetectors 224 (see FIG. 2A) or one or more second reference photodetectors 230 (see FIG. 2B), which may be, for example, one or more blue filter coated photodiodes.
- the second emission light 332 emitted by the interferent indicator 209 may be measured by one or more interferent photodetector 228 (e.g., one or more yellow 7 filter coated photodiodes).
- the analyte sensor 100 may include one or more drug-eluting polymer matrices 2204 on all or a portion of an external surface of the sensor housing 102.
- one or more therapeutic agents may be dispersed within the one or more drug eluting polymer matrices 2204.
- the one or more therapeutic agents may reduce or stop the migration of neutrophils from entering the space in which the analyte sensor 100 has been implanted and, thus, reduce or stop the production of hydrogen peroxide and fibrotic encapsulation.
- the one or more therapeutic agents may reduce deterioration of the one or more indicator elements 106 (e.g., indicator elements 106a and 106b).
- the one or more therapeutic agents which may be dispersed within the drug eluting polymer matrix 2204, may include one or more antiinflammatory drugs, such as, for example, non-steroidal anti-inflammatory drug (e.g., acetylsalicyiic acid (aspirin) and/or isobutylphenylpropanoie acid (ibuprofen)).
- the one or more therapeutic agents dispersed within the drug-eluting polymer matrix may include one or more glucocorticoids.
- the one or more therapeutic agents may include one or more of dexamethasone, triamcinolone, betamethasone, methylprednisolone, beclometasone, fludrocortisone, derivatives thereof, and analogs thereof.
- the one or more therapeutic agents may reduce the production of hydrogen peroxide by neutrophils and macrophages.
- FIGS. 24A-24D show optical and fluorescence images of the analyte sensor 100 after localized oxidation.
- FIGS. 24 A and 24B show the underlying sensor optics and a bright field image of the analyte sensor 100, respectively.
- FIG. 24C shows fluorescence imaging of the analyte indicator 207 with a localized decrease in fluorescence due to localized oxidation near the bottom of the analyte indicator 207
- FIG. 24D shows fluorescence imaging of the interferent indicator 209 with a corresponding localized increase in fluorescence due to the localized oxidation near the bottom of the interferent indicator 209.
- the fluorescence imaging shown in FIGS. 24C and 24D demonstrate that a decrease in the first emission light 331 emitted by the analyte indicator 207 due to localized oxidation is spatially correlated with an increase in the second emission light 332 emitted by the interferent indicator 209.
- FIGS. 25A-25D show in vivo measurements from the sensing areas 2202a, 2202c, 2202b, and 2202d, respectively, of the analyte sensor 100 shown in FIG. 22.
- the sensing areas 2202a and 2202c may be long end distal (LED) and long end central (LEG) sensing areas of the analyte sensor 100, respectively, and the sensing areas 2202b and 2202d may be short end central (SEC) and short end distal (SED) sensing areas of the analyte sensor, respectively.
- the measurements may include measurements of the first and second excitation lights 329 and 330 and the first and second emission lights 331 and 332.
- the analyte sensor 100 shown in FIG. 22 may combine an interferent indicator 209 used to measure oxidation and redundant sensing areas 2202a-2202d to obtain analyte values using weighted averaging.
- the analyte monitoring system 50 e.g., the transceiver 101 of the analyte monitoring system 50
- the analyte monitoring system 50 may selectively utilize information (e.g., measurements) from the sensing areas 2202 from the multi-analyte (e.g, glucose and oxidation), multi-site array to calculate glucose values.
- information e.g., measurements
- FIG. 26A shows individual glucose concentrations calculated from the sensing areas 2202a-2202d of the analyte sensor 100 shown in FIG. 22 individually (e.g., based on measurements of one or more of the first and second excitation lights 329 and 330 and the first and second emission lights 331 and 332 from the sensor areas 2202 individually), and
- FIG. 26B shows combined glucose concentrations calculated based on a weighted average of the individual glucose concentrations.
- the sensing areas 2202a and 2202c may be long end distal (LED) and long end central (LEG) sensing areas of the analyte sensor 100, respectively, and the sensing areas 2202b and 22Q2d may be short end central (SEC ) and short end distal (SED) sensing areas of the analyte sensor, respectively.
- the analyte monitoring system 50 with the analyte sensor 100 shown in FIG. 22 had an overall MARD of 9.2% at 90-days and 9.3% at 180-days, with one calibration per week using finger stick glucose measurements as a reference.
- these studies show that the multiple sensing channels of the analyte sensor 100 shown in FIG.22 enable accurate measurement of glucose, as well as assessment of oxidation of the indicator element 106. By detecting these multiple analytes (e.g., glucose and oxidation), accuracy can be maintained for up to 365 days with a significant reduction in calibration to one time per week.
- the analyte sensor 100 may include a first indicator element that includes the analyte indicator 207 and a second indicator element that includes the interferent indicator 209.
- the analyte indicator 207 and the interferent indicator 209 may be spatially separated from one another.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Microbiology (AREA)
- Plasma & Fusion (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3220256A CA3220256A1 (en) | 2021-05-27 | 2022-05-26 | Detecting and correcting for interference in an analyte monitoring system |
JP2023573140A JP2024519422A (en) | 2021-05-27 | 2022-05-26 | Detection and correlation of interferences in analyte monitoring systems - Patents.com |
EP22812116.6A EP4348272A1 (en) | 2021-05-27 | 2022-05-26 | Detecting and correcting for interference in an analyte monitoring system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163193784P | 2021-05-27 | 2021-05-27 | |
US63/193,784 | 2021-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022251427A1 true WO2022251427A1 (en) | 2022-12-01 |
Family
ID=84229175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/031035 WO2022251427A1 (en) | 2021-05-27 | 2022-05-26 | Detecting and correcting for interference in an analyte monitoring system |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4348272A1 (en) |
JP (1) | JP2024519422A (en) |
CA (1) | CA3220256A1 (en) |
WO (1) | WO2022251427A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210052202A1 (en) * | 2017-04-19 | 2021-02-25 | Senseonics, Incorporated | Detecting and correcting for changes to an analyte indicator |
US20210137420A1 (en) * | 2019-11-13 | 2021-05-13 | Senseonics, Incorporated | Interferent detection in an analyte monitoring system |
-
2022
- 2022-05-26 CA CA3220256A patent/CA3220256A1/en active Pending
- 2022-05-26 WO PCT/US2022/031035 patent/WO2022251427A1/en active Application Filing
- 2022-05-26 EP EP22812116.6A patent/EP4348272A1/en active Pending
- 2022-05-26 JP JP2023573140A patent/JP2024519422A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210052202A1 (en) * | 2017-04-19 | 2021-02-25 | Senseonics, Incorporated | Detecting and correcting for changes to an analyte indicator |
US20210137420A1 (en) * | 2019-11-13 | 2021-05-13 | Senseonics, Incorporated | Interferent detection in an analyte monitoring system |
Also Published As
Publication number | Publication date |
---|---|
CA3220256A1 (en) | 2022-12-01 |
JP2024519422A (en) | 2024-05-13 |
EP4348272A1 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11517230B2 (en) | Detecting and correcting for changes to an analyte indicator | |
US10874339B2 (en) | System and method for measuring an amount of blood and/or clotting in a pocket surrounding an implantable medical device | |
US12000784B2 (en) | Identification of degradative species | |
US20210137420A1 (en) | Interferent detection in an analyte monitoring system | |
US20220287597A1 (en) | Detecting and correcting for interference in an analyte monitoring system | |
US10912498B2 (en) | Fluorescence-based sensor with multiple indicator grafts | |
US20240041366A1 (en) | Detecting and correcting for interference in an analyte monitoring system | |
WO2022251427A1 (en) | Detecting and correcting for interference in an analyte monitoring system | |
WO2024077241A2 (en) | Detecting and correcting for interference in an analyte monitoring system | |
EP4191423A1 (en) | Remotely-powered sensing system with multiple sensing devices | |
EP4064988A1 (en) | Methods and systems for reducing difference between calculated and measured analyte levels | |
US20190159704A1 (en) | Extending battery life | |
US11761953B2 (en) | Mediation of in vivo analyte signal degradation | |
CA3211865A1 (en) | Methods and systems for reducing difference between calculated and measured analyte levels | |
WO2020092897A1 (en) | Drug eluting matrix on analyte indicator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22812116 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3220256 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023573140 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022812116 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022812116 Country of ref document: EP Effective date: 20240102 |